Jazz Pharmaceuticals (JAZZ) Earnings Date & Reports

Key Takeaways

• Record quarterly revenue: Jazz Pharmaceuticals reported total revenue of $1.21 billion in the second quarter of 2026, a 16% year-over-year increase that exceeded Wall Street estimates.
• Adjusted EPS falls short: Non-GAAP (adjusted) earnings per share came in at $5.71, missing the consensus forecast of $6.18, partly due to $0.94 per share in acquired IPR&D (in-process research and development) charges tied to new collaboration agreements.
• Full-year guidance raised: Management lifted its 2026 revenue guidance range to $4.60 billion–$4.75 billion, up sharply from the prior $4.25 billion–$4.50 billion, reflecting strength across sleep, epilepsy, and oncology franchises.
• Broad commercial momentum: Xywav grew 13% to $471 million with 525 net new patient additions, Epidiolex rose 16% to $292 million, and the oncology portfolio surged 32% year over year, led by Zepzelca and the newly launched Modeyso.
• Regulatory catalyst ahead: The FDA's target decision date (PDUFA date) for zanidatamab in first-line HER2-positive gastroesophageal adenocarcinoma is August 25, 2026, and Jazz expressed high confidence in approval and immediate launch readiness.
• Stock climbs after hours: Shares rose 3.74% in after-hours trading following the release, approaching the 52-week high, as investors focused on the revenue beat and raised guidance.

Earnings Context and Why It Matters

Jazz Pharmaceuticals entered its second quarter of 2026 with elevated expectations. The company was coming off a first quarter in which it had crushed earnings estimates by 37%, and its stock had more than doubled from its 52-week low of $105. With the August 25 regulatory decision on zanidatamab — widely viewed as the company's most significant pipeline catalyst — just weeks away, this earnings report carried outsized importance. Investors were looking for confirmation that Jazz's core commercial franchises could sustain double-digit growth and that the company had the financial firepower to support an immediate product launch. The second quarter results delivered a mixed but ultimately bullish message: record revenue and raised full-year guidance signaled operational strength, even as an EPS miss reminded the market that investment in the pipeline carries near-term costs.

Reported Results

Jazz Pharmaceuticals posted total revenues of $1.208 billion for the second quarter of 2026, marking a 16% increase from $1.046 billion in the same period last year and setting a new quarterly record. The top-line figure handily beat the consensus analyst estimate of approximately $1.11 billion. On the bottom line, the company reported GAAP (Generally Accepted Accounting Principles) earnings of $2.78 per share and non-GAAP adjusted earnings of $5.71 per share. The adjusted EPS figure fell short of the $6.18 Wall Street consensus by $0.47, though it included a $0.94-per-share charge tied to acquired IPR&D expenses from new collaboration and asset purchase agreements with AbCellera and Werewolf Therapeutics.

Breaking down the commercial performance, Xywav — the low-sodium oxybate therapy for narcolepsy and idiopathic hypersomnia — generated $471 million in net product sales, a 13% year-over-year increase. The product added approximately 525 net patients during the quarter, bringing total active patients to roughly 17,125, with growth balanced across both the narcolepsy and idiopathic hypersomnia indications. Epidiolex, the company's cannabidiol-based epilepsy treatment, delivered $292 million in sales, up 16% from the prior year, driven by strong demand in both pediatric and adult patient populations, including long-term care settings.

The oncology portfolio was a standout, with combined revenues climbing 32% year over year. Zepzelca posted $106 million in sales, a 42% increase fueled by adoption in the first-line maintenance setting for extensive-stage small cell lung cancer (ES-SCLC). Modeyso, the recently launched treatment for H3 K27M-mutant diffuse midline glioma, contributed $48 million in its first full year on the market, with more than 600 patients treated since launch. Ziihera added $15 million in biliary tract cancer sales. Operating cash flow for the first half of 2026 reached $824 million, and the company ended the quarter with $2.2 billion in cash and investments.

AI Screener

For investors looking to identify compelling opportunities in the biopharmaceutical sector and beyond, Tickeron's AI Screener offers a powerful, AI-driven stock and ETF discovery platform. The tool enables traders and investors to scan thousands of securities using customizable filters such as industry classification, market capitalization, technical indicators, price patterns, volatility metrics, and proprietary AI-powered signals. Whether you are searching for breakout candidates, stocks exhibiting bullish technical patterns, or under-the-radar names with strong fundamentals, the AI Screener is designed to surface actionable trade ideas and market opportunities with greater speed and precision than traditional manual screening methods. Explore the AI Screener today to enhance your research workflow.

Market Reaction and Investor Sentiment

Investors appeared to look past the headline EPS miss and focus on the strength of the underlying business. Jazz Pharmaceuticals shares rose 3.74% in after-hours trading on August 3, reaching $261 and approaching the 52-week high of $261.30. During the regular session, the stock had closed at $251.58, down 0.5%. The positive after-hours move reflected confidence in the revenue beat, the raised full-year guidance, and management's express confidence regarding the upcoming zanidatamab regulatory decision. With 18 of 20 sell-side analysts rating the stock a Buy and a mean price target near $267 heading into the report, institutional sentiment remained broadly constructive. The market's willingness to reward the stock despite the EPS shortfall suggests that investors are prioritizing revenue momentum and the zanidatamab catalyst over quarter-to-quarter earnings variability driven by deal-related charges.

Forward Outlook and Key Factors to Monitor

Jazz Pharmaceuticals' raised 2026 revenue guidance of $4.60 billion to $4.75 billion now anticipates double-digit year-over-year growth from both Xywav and the combined epilepsy and oncology franchises. Management attributed the upward revision to stronger-than-expected Xywav performance and sustained demand across the portfolio, and the rare-sleep revenue outlook was lifted to $2.025 billion–$2.125 billion.

The most consequential near-term event for the company and its investors is the FDA's PDUFA target action date of August 25, 2026, for zanidatamab in first-line HER2-positive gastroesophageal adenocarcinoma (GEA). Jazz has indicated it is fully prepared for an immediate commercial launch upon approval, with a customer-facing team already in place. The GEA opportunity represents approximately 63,000 annual cases across the U.S., Europe, and Japan, and positive Phase 3 data published in The New England Journal of Medicine showed median overall survival of 26.4 months for the zanidatamab-containing combination regimen.

Beyond zanidatamab, several other developments merit attention. In the third quarter, Jazz expects to report top-line results from the second interim overall survival analysis for the doublet regimen in the HERIZON-GEA-01 trial and to submit a labeling supplement to remove Zepzelca's second-line indication following the LAGOON trial results — a move that could accelerate the erosion of second-line sales but sharpen focus on the growing first-line maintenance opportunity. Meanwhile, the Phase 3 ACTION trial of Modeyso is progressing toward an interim overall survival analysis expected in the first half of 2027. On the cost side, investors should monitor SG&A (selling, general, and administrative) expenses, which are now guided higher at $1.33 billion–$1.37 billion on a non-GAAP basis, reflecting investments in commercial infrastructure and launch preparations. The company's strong cash position and $885 million in undrawn revolving credit capacity provide meaningful financial flexibility for additional business development, which management has signaled could materialize before year-end.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations